Recent Analysts’ Ratings Updates for ArQule (ARQL)

Several brokerages have updated their recommendations and price targets on shares of ArQule (NASDAQ: ARQL) in the last few weeks:

  • 6/19/2019 – ArQule had its price target raised by analysts at Royal Bank of Canada to $12.00. They now have an “outperform” rating on the stock.
  • 6/15/2019 – ArQule was given a new $12.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 6/14/2019 – ArQule was given a new $11.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 6/14/2019 – ArQule had its price target raised by analysts at Roth Capital from $10.00 to $13.00. They now have a “buy” rating on the stock.
  • 6/13/2019 – ArQule was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/5/2019 – ArQule was given a new $11.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 5/31/2019 – ArQule was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
  • 5/29/2019 – ArQule had its price target raised by analysts at B. Riley from $6.75 to $11.00. They now have a “buy” rating on the stock.
  • 5/28/2019 – ArQule had its “buy” rating reaffirmed by analysts at Roth Capital.
  • 5/24/2019 – ArQule was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/7/2019 – ArQule was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
  • 5/2/2019 – ArQule was given a new $10.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 4/30/2019 – ArQule was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of NASDAQ ARQL opened at $10.82 on Wednesday. ArQule, Inc. has a 12 month low of $2.23 and a 12 month high of $11.11. The stock has a market capitalization of $1.18 billion, a P/E ratio of -67.63 and a beta of 1.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.45 and a current ratio of 6.45. The company’s fifty day moving average is $7.48.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $1.70 million. ArQule had a negative return on equity of 28.90% and a negative net margin of 83.15%. Research analysts anticipate that ArQule, Inc. will post -0.37 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co NY lifted its position in shares of ArQule by 4.7% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 32,403 shares of the biotechnology company’s stock worth $155,000 after buying an additional 1,459 shares during the period. Marshall Wace LLP bought a new position in shares of ArQule during the 1st quarter worth approximately $1,567,000. Meitav Dash Investments Ltd. lifted its position in shares of ArQule by 300.0% during the 1st quarter. Meitav Dash Investments Ltd. now owns 40,000 shares of the biotechnology company’s stock worth $192,000 after buying an additional 30,000 shares during the period. Handelsbanken Fonder AB lifted its position in shares of ArQule by 10.0% during the 1st quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock worth $5,269,000 after buying an additional 100,000 shares during the period. Finally, Fosun International Ltd bought a new position in shares of ArQule during the 1st quarter worth approximately $642,000. 72.21% of the stock is owned by hedge funds and other institutional investors.

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.

Featured Article: Cash Flow

Receive News & Ratings for ArQule Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc and related companies with MarketBeat.com's FREE daily email newsletter.